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Summary: In comparison to a triple wavelength procedure, the dual wavelength method for the determination of
plasma haemoglobin concentration using the ACA analyzer showed considerable interference with hypertriglycerid-
aemic (triacylglycerols > 2.3 mmol/1) plasma. By addition of isolated human lipoprotein fractions to normotriglyc-
eridaemic plasma, chylomicrons were identified as a major source of interference with the ACA plasma haemo-
globin method, whereas VLDL was without effect up to a triacylglycerol concentration of 5.7 mmol/1. Airfuge
ultracentrifugation proved to be a reliable means for removal of interfering lipid. We conclude that the extent of
lipid interference with the ACA plasma haemoglobin method is highly dependent on the type of lipoprotein present.
An accurate measurement of plasma haemoglobin concentrations in non-fasting plasma can only be ensured after
lipid removal through airfuge ultracentrifugation.
Introduction
Plasma haemoglobin can be quantified on the ACA (Du
Pont) analyzer using a dual wavelength method. The
original application of Golf, Schneider, Friemann et al.
(1) involved measuring the haemoglobin absorbance at
540 nm and correcting for background absorption at 600
nm. Recently, the manufacturer modified the procedure
to make use of the potentially more specific measure-
ment with filter 9 (577 nm) in combination with filter
10 (600 nm) (2).
Bilirubin, triacylglycerols, carboxyhaemoglobin and
myoglobin were investigated by the manufacturer as po-
tential causes of interference. In the case of plasma tria-
cylglycerol it was claimed that concentrations up to
442.5 mg/dl (5.0 mmol/1) yield an interference below
10%. Since it is well known that clinical chemical as-
says based on photometric absorption measurements can
be affected by hyperlipidaemia (3) we have studied in
detail the nature and extent of lipid interference on the
determination of plasma haemoglobin concentrations
using the ACA SX plasma haemoglobin method and
have compared the results with those from an estab-
lished triple wavelength method (4).
Materials and Methods
Routine patient blood samples (n = 32) were collected into plastic
tubes containing ammonium heparinate (S-Monovette 5.5 ml, Sar-
stedt, post box 1220, D-51582 Numbrecht, Germany). Plasma was
separated by low speed centrifugation at 3000 g for 10 min.
Photometr ic methods
Comparison method
The triple wavelength comparison method was carried out using a
DU-7500 photometer (Beckman Instruments GmbH, Frankfurter
Ring 115, D-80807 München, Germany) with automatic calcula-
tion of concentration values. Undiluted plasma samples were mea-
sured simultaneously at the main wavelength of 578 nm and the
two subtraction wavelengths of 598 and 562 nm. The haemoglobin
concentration was calculated according to the method of Kahn et
al. (5) using the respective factors published by Fairbanks et al. (4).
Hb = 1000 · [1.550 · A578 - 0.689 · A598 - 0.861 - A562] mg/1.
When absorbance values > 2.0 occurred, the sample was diluted
with 2 volumes of isotonic NaCl and results were multiplied by 3.
Test method
The dual wavelength method for measuring plasma haemoglobin
concentration on the ACA SX analyzer (Du Pont) was performed
according to the manufacturer's instructions. Filter 9 (577 nm) was
used for the main wavelength and filter 10 (600 nm) for the refer-
ence wavelength (2). Determinations were performed as single
measurements.
!) This investigation was supported by Du Pont de Nemours
(Deutschland) GmbH, Du Pont Straße l, D-61343 Bad Homburg,
Germany.
Calibration of the test method
ACA result calculation was defined by the use of calibration
factors, with CO and Cl representing the instrument coefficients
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for slope and intercept in linear calibration procedures. For calibra-
tion of the dual wavelength haemoglobin method, these factors
have to be set by the following procedure:
1. Enter coefficients for CO and Cl (for option, enter the values as
specified in the appendix).
2. Freshly collect at least 10 clear patient hcparinate plasma sam-
ples (triacylglyccrol concentrations < 2.3 mmol/1) with plasma
haemoglobin values assigned from the triple wavelength method.
Triple wavelength haemoglobin values should be in the concentra-
tion range between 300 and 1200 mg/1 for these samples. Apply
these samples to the ACA measurement in an undiluted fashion.
3. Apply the non-parametric linear regression procedure (6) to ob-
tain slope b and intercept a of the concentration data for these
samples, with the triple wavelength method values entered as x-
values and the values of the ACA method as y-values. For the
procedure to be applicable, the correlation coefficient r is expected
to yield a value > 0.990.
4. Modify the calibration coefficients CO and Cl of the ACA ac-
cording to the following calculation formulae: C0new = C00id - a;
Clncw = Clold/b. Enter these values using mode 41 of the ACA an-
alyzer.
Example: Initial CO = -7.47, initial Cl = -27.79.
a (obtained from regression analysis ) = 2.0, b = 1.057.
Result (to be entered in mode 41 of the ACA instrument):
C0new = C0old - a = -7.47 - 2.0 = -9.47;
Clnew = Clold/b = -27.79/1.057 = -26.29.
Performance control
Instrument performance was monitored with the CoS04 absorbance
test solution supplied by the instrument manufacturer. Performing
this dual-wavelength procedure as recommended, we obtained a
between-days coefficient of variation of 0.4% (n = 21). With an
in-house plasma-derived precision control of 324 mg/1 plasma hae-
moglobin, the between-days coefficient of variation was 2.1%
Human chylomicron and VLDL preparation
A pool of fresh lipaemic human plasma from blood donors was
used for preparation of human chylomicron and VLDL fractions.
Purification was achieved by fractionation according to particle
density. One volume of plasma was carefully overlayered with one
volume of 9 g/1 NaCl, 0.2 g/1 NaN3, 1 mmol/1 EDTA. After centri-
tugation at 30000g for 2 h at 15 °C the pale yellow supernatant
(Sf > 400, predominantly chylomicrons) was recovered by tube
slicing. The infranatant was again overlayered with an equal vol-
ume of 9 g/1 NaCl, 0.2 g/1 NaN3, 1 mmol/1 EDTA and recentriruged
for 16 h at 10°C and a relative centrifuge force of 110 000 g to
yield the lipoprotein fraction Sf 20-400 (i.e. predominantly
VLDL).
Both fractions were recentriruged at their respective density for
1 6 h at 1 1 0 000 g and 1 0 °C and the supernatants recovered by tube
slicing. These preparations were then used for the lipid interference
measurements. Concentrations of triacylglycerols and cholesterol
were 24.1 mmol/1 triacylglycerols and 12.2 mrnol/1 cholesterol in
the chylomicron fraction and 21.2 mmol/1 triacylglycerols and 16.8
mmol/1 cholesterol in the VLDL fraction. The size of the lipopro-
tein particles was determined with a NICOMP 70 laser particle
sizer (Particle Analytic Me ger te GmbH, Olpener Stra e 150,
D-50933 K ln, Germany).
Other procedures
Lipaemic plasma samples were clarified by flotation of triacylglyc-
erol-rich lipoproteins using an air-driven ultracentrifuge (Airfuge,
rotor A 100/30, both from Beckman Instruments GmbH, Frank-
furter Ring 115, D-80807 M nchen, Germany). For each sample,
two tubes were filled with 175 μΐ of plasma and centrifuged for 20
min at 160000g yielding ca. 250 μΐ of clear delipidated plasma
for Hb determination in an ACA micro-cup.
Haemolysates were prepared by addition of a 10-fold excess of
cold Na2C03-solution (0.1 g/1) to EDTA-anticoagulated human
blood samples. After an incubation of 30 min, the solution was
sonified with a tip sonicator (Branson Ultrasonic S. A., Chemin du
Faubourg-de-Cruseilles 9, CH-1228 Carouge-Geneve, Switzerland)
set at medium performance for 3 X 20 s and then filtered through a
0.2 μηι ultrafilter (Schleicher and Schuell, Hahnestra e 3, D-37586
Dassel, Germany).
Triacylglycerol and cholesterol concentrations were determined on
a Hitachi 747 random access clinical chemical analyzer (Hitachi
Ltd. Instrument Division, 882, Ichige, Katsuta-shi, Ibaraki-ken, 312
Japan) using coupled glycerol 3-phosphate oxidase/peroxidase and
cholesterol oxidase/peroxidase photometric tests (Rolf Greiner Bio-
Chemica, Wiesenstra e 45, D-65558 Flacht, Germany) with
parameter settings as recommended by the reagent manufacturer.
For method comparison, the non-parametrical linear regression
procedure of Passing & Bablok (6) was performed using the statis-
tical data analysis software package EVAPAK (7), obtained by
courtesy of Mr. W. Bablok (Boehringer Mannheim GmbH, Sand-
hofer Stra e 116, D-68305 Mannheim, Germany).
Statistical tests for identity of data distribution were performed
using the Mann-Wliitney U-test procedure.
Results
Lipid interference in patient samples
investigated by method comparison
Plasma haemoglobin concentrations were determined in
32 heparinate plasma samples with triacylglycerol con-
centrations ranging from 0.62 to 8.00 mmol/1 (median
= 3.47 mmol/1) using both the triple wavelength pro-
cedure and the ACA plasma haemoglobin method.
Plasma haemoglobin concentrations were significantly
higher (p < 0.001) when measured with the latter
method, yielding values of 60 (40-100) mg/1 [median
(16.—84. percentile)] in comparison to 20 (10—30) mg/1
for the triple wavelength method. Furthermore, a poor
correlation (r = 0.447, y = 2.0 χ +10 mg/1) was ob-
served between the haemoglobin concentration values
obtained using the two different procedures. Triacylglyc-
erol-rich lipoproteins were then separated from the
plasma using an air-driven ultracentrifuge, and plasma
haemoglobin concentrations were once again deter-
mined with the ACA plasma haemoglobin method. The
median plasma haemoglobin concentration value after
delipidation was 40 (20-50) mg/1 using the ACA
method. Although this was still significantly greater
(p < 0.005) than the value obtained with the comparison
method, there was now a good correlation between the
ACA method and the triple wavelength method
(r = 0.855, y = 1.0 χ + 10 mg/1).
When the values determined with the triple wavelength
method were subtracted from those obtained using the
ACA plasma haemoglobin procedure and plotted against
the respective plasma triacylglycerol concentrations of
each sample (fig. 1), substantial positive deviations of
the ACA values from the triple wavelength method val-
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Fig. 1 Difference between the ACA plasma haemoglobin and tri-
ple wavelength method haemoglobin in relation to the plasma tri-
acylglycerol concentration.
[A] Untreated patient samples
[o] After airfuge treatment
In each graph, the abscissa represents the triacylglycerol concentra-
tion of the native patient plasma sample. The difference between
the ACA plasma haemoglobin concentration value and the triple
wavelength reference method value is given by the ordinate.
ues were observed with the native plasma. While there
is an apparent trend to increased deviation at elevated
triacylglycerol concentrations, there is obviously a wide
degree of variation in this deviation even at triacylglyc-
erol concentrations around 3.4 mmol/l.
After separation of the triacylglycerol-rich lipoproteins
from the plasma, the ACA plasma haemoglobin method
displayed only marginally higher values than the triple
wavelength procedure irrespective of the triacylglycerol
concentration. We thus achieved a substantial reduction
of the overall value differences between the ACA
plasma haemoglobin method and the triple wavelength
method as indicated by a median (16th—84th percentile)
difference of 10 (0-20) mg/1 after delipidation com-
pared with a value of 30 (20—70) mg/1 obtained pre-
viously. The distribution of the plasma haemoglobin dif-
ferences for these two populations was significantly dif-
ferent at the p < 0.001 level. Furthermore, the depen-
dence of the differences between the two methods upon
the triacylglycerol concentration decreased after ultra-
centrifugation: the slope was 15.4 (confidence interval
9.82-23.3) before and 5.04 (confidence interval 2.39-
9.91) after ultracentrifugation.
Influence of triacylglycerol-rich lipoprotein
preparations on the ACA plasma haemoglobin
procedure
Both VLDL and chylomicrons were isolated from lipae-
mic plasma by sequential ultracentrifugation. The prop-
erties of the isolated human lipoprotein fractions are pre-
sented in table 1. As expected, the chylomicron fraction
contained particles of a greater size than those in the
VLDL fraction.
Increasing amounts of either VLDL or chylomicrons
were added to a plasma pool and plasma haemoglobin
concentrations were then determined using the ACA
procedure. The results were plotted against the respec-
tive triacylglycerol concentrations (fig. 2). Addition of
increasing amounts of chylomicrons to a normotriglyc-
eridaemic plasma sample pool (triacylglycerol concen-
tration = 0.62 mmol/l) led to a linear increase in the
ACA plasma haemoglobin concentration value. At a fi-
nal triacylglycerol concentration of 5.7 mmol/l, the ap-
parent plasma haemoglobin concentration was around
160 mg/1 greater than that of the original sample. In
contrast to chylomicrons, addition of VLDL resulted in
a much lower interference with the plasma haemoglobin
concentration determination. At a final triacylglycerol
concentration of 5.7 mmol/l, the ACA plasma haemo-
Tab. 1 Characterization of purified lipoprotein fractions.
Lipoprotein component Chylomicron-rich VLDL
preparation
Electrophoresis Predominantly
chylomicrons
Predominantly
VLDL
Composit ion
Triacylglycerols (mmol/l) 24.1
Cholesterol (mmol/l) 12.2
Particle radius
Mean(SD)(nm) 119(62)
21.2
16.8
55 (26)
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globin concentration value was only increased by around
30 mg/1 (fig. 2).
Airfuge treatment of samples from either series led to
the reduction of the ACA plasma haemoglobin concen-
tration values to concentrations similar to those obtained
prior to lipoprotein addition irrespective of the extent of
interference observed.
The effect of lipoprotein addition to the plasma pool was
analyzed by a non-parametric linear procedure accord-
ing to Passing & Bablok (6). The slope from the chy-
lomicron addition experiment of 29.3 (confidence in-
terval 26.3-32.9) was reduced to a value of 3.27 (confi-
dence interval 0.00-8.23) after removal of the triacyl-
glycerol-rich lipoprotein, indicating almost complete
elimination of the triacylglycerol interference. The ex-
tent of the VLDL interference was much lower, with an
initial slope value of 5.40 (confidence interval 3.27-
9.74). After ultracentrifugation, all seven data points
yielded an identical haemoglobin concentration of 30
mg/1 irrespective of the original triacylglycerol concen-
tration. The influence of the two different lipoproteins
on the determination of haemoglobin concentrations was
also investigated in samples containing normal and ele-
vated plasma haemoglobin concentration levels. The re-
sults are presented in figure 3. The plot shows that chy-
lomicrons in particular can cause substantial interference
with the ACA method, relative to the amount of haemo-
globin present. In contrast, the presence of VLDL up to
triacylglycerol concentrations of 5.7 mmol/1 did not
cause a clinically significant lipid interference.
The addition of increasing amounts of chylomicrons to
plasma pools containing 30, 110, and 320 mg/1 plasma
haemoglobin produced slope values of 30.6, 28.7, and
27.7 (confidence intervals 27.3-33.6, 25.0-33.1, and
18.9-3Γ.2), respectively (fig. 3a). In contrast, VLDL
addition with the three plasma haemoglobin concentra-
tions yielded lower slope values of 6.20, 4.87, and 4.51
(confidence intervals 4.69-9.20, 0.00-6.90, and 0.00-
11.8), respectively (fig. 3b). These data confirm the re-
sults obtained from figure 2, showing much greater in-
terference from chylomicrons in comparison to VLDL.
Discussion
Interferences in clinical chemistry instrumentation are
easily visualized in the form of so-called interferographs
(8). They offer the potential advantage of arithmetical
compensation of the interferant under investigation.
With ACA analyzers, a thorough analysis of several in-
terferants with a number of assays has been published
(8), however one limitation was that an artificial lipid
mixture was used to generate sample turbidity. Further-
more, no published data exist on the effect of lipaernic
samples in the ACA plasma haemoglobin procedure.
It is well known that several mechanisms contribute to
the observed interference of lipaemia on photometric ab-
sorption measurements. One mechanism is dependent on
the presence of turbid, light-scattering sample compo-
nents (3). These light-scattering phenomena are related
to particle properties as defined by radius and criteria of
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Fig. 2 Influence of supplementation of pool plasma with purified
lipoprotein fractions on the ACA plasma haemoglobin method.
Purified lipoprotein preparations were added to a pool plasma to
[-Δ-] Purified human chylomicrons, before delipidation.
y = 11.16mg/l + 29.3 · x.
[-A-] Purified human chylomicrons, after delipidation.
y = 26.!3mg/l + 3.27 · x.
give the final triacylglycerol concentration given in the abscissa.
ACA plasma haemoglobin values were determined before and after
delipidation by airfuge centrifugation.
[-0-] Purified human VLDL, before delipidation.
y = 26.52 mg/l + 5.40 · x.
[-0-] Purified human VLDL, after delipidation.
y = 30 mg/l + 0.00 · x.
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shape. It can therefore be surmised that clinical chemi-
cal methods relying on photometric measurement will
be differentially affected by different lipoprotein sub-
fractions. Using whole blood as the matrix for haemo-
globin concentration determinations, differential inter-
ference effects of lipoprotein subfractions have been
known for a long time (9). The aim of this present
investigation was therefore to investigate the influence
of lipaemia, and in particular, the effect of different
lipoprotein species on the measurement of plasma hae-
moglobin concentration using the ACA haemoglobin
method.
In comparison to a triple wavelength procedure, the
ACA method showed considerable interference with
hypertriglyceridaemic (> 2.3 mmol/1) plasma. There
was, however, substantial variation in the extent of this
interference even at similar plasma triacylglycerol con-
centrations (fig. 1). Since light scattering is proportional
to the square of the particle volume (10) and therefore
to the sixth power of the radius, it is expected that the
size distribution of the lipoprotein particles will be im-
portant for the extent of the interference observed, Chy-
lomicrons which are synthesized post-prandially in the
intestine are the largest lipoprotein particles. Addition of
purified chylomicrons to pool plasma caused consider-
able interference with the ACA method for the determi-
nation of plasma haemoglobin concentration. VLDL is
synthesized continuously in the liver and carries endoge-
nously synthesized triacylglycerol as well as cholesterol.
Although highly heterogeneous, it is generally of smaller
size than the chylomicrons (tab. 1). Purified VLDL was
1 2 3 4 5
Triacylglycerol concentration [mmol/l]
found to have no major effect on the determination of
plasma haemoglobin concentration using the ACA
method up to a triacylglycerol concentration of 5.7
mmol/l.
Since preanalytical phenomena (e.g. sampling arti-
facts) are of major importance for the determination of
the plasma haemoglobin concentration, two threshold
values have been suggested ( I I ) for clinical evaluation
of a single plasma haemoglobin concentration mea-
surement. In addition to the upper reference limit (100
mg/1), an elevated clinical decision value has been
recommended, which has to be considered to exclude
the presence of extravasal haemolysis. This value is
considered to be 200 mg/1 (11). We therefore investi-
gated the influence of triacylglycerol-rich lipoproteins
on plasma haemoglobin concentration values in the
low reference range, at the upper reference limit of
100 mg/1, and at a pathological plasma haemoglobin
concentration. A plasma haemoglobin concentration
value of 100 mg/1 will be falsely classified as patho-
logical, that is, above the clinical decision limit of
200 mg/1, at chylomicron triacylglycerol concentrations
> 4.0 mmol/l. The influence of VLDL on the determi-
nation of plasma haemoglobin concentration values
both within the reference range and at pathological
values was found to be minimal up to a VLDL triacyl-
glycerol concentration of 5.7 mmol/l.
Furthermore, the statistical evaluation confirms that
lipoprotein interference is linear and additive for a spe-
cific type of lipoprotein in combination with plasma
haemoglobin content.
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Fig. 3 Influence of triacylglycerol-rich plasma lipoproteins on ACA plasma haemoglobin
concentration determination at different haemoglobin values.
a) Purified chylomicrons
[-Δ—] human plasma pool with a plasma haemoglobin concen-
tration of 30 mgA.
y = 9.23 mg/l + 30.6 · x.
[-^-] human plasma pool supplemented with haemolysate to
yield a final plasma haemoglobin concentration of
HO mg/l.
y = 85.51 mg/l + 28.7-X.
[—G-] human plasma pool supplemented with haemolysate to
yield a final plasma haemoglobin concentration of
320 mg/l.
y = 295.31 mg/l + 27.7 · x.
The dashed line [ ] indicates the upper reference interval,
b) Purified VLDL
[-Δ-] human plasma pool with a plasma haemoglobin concen-
tration of 20 mg/l.
y = 13.08 mg/l + 6.20 · x.
[-^-] human plasma pool supplemented with haemolysate to
yield a final plasma haemoglobin concentration of
120 mg/l.
y = 114.21 mg/l + 4.87 · x.
[—O—] Human plasma pool supplemented with haemolysate to
yield a final plasma haemoglobin concentration of
350 mg/l.
y = 344.33 mg/l +4.51 · x,
the dotted line [ ] represents the corresponding decision value.
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Based on these results we conclude that the extent of
the lipid interference is highly dependent on the lipo-
protein species present in the plasma samples. Chy-
lomicrons, but not VLDL, exhibit considerable inter-
ference in physiological samples. Plasma haemoglobin
concentrations can therefore b'e correctly determined
in non-fasting, chylomicron-containing plasma using
the ACA analyzer only after prior delipidation. Several
methods have been suggested for the clarification of
hyperlipidaemic samples. These include ultracentrifti-
gation, detergent addition, chemical precipitation, ex-
traction, chromatography, and enzymatic treatment.
Most of these involve off-line sample treatment for-
separation of lipid constituents, however some meth-
ods have been shown to be compatible with the rea-
gents applied in current clinical chemical photometric
assays (12). The present data demonstrate that airfuge
ultracentrifiigation is an effective procedure for re-
moval of lipid interference with the ACA plasma hae-
moglobin determination method.
Appendix
Settings3 for the dual wavelength plasma haemoglobin concentra-
tion determination on the ACA SX analyzer [adapted as method
#91]
CO
Cl
PI
P2
P3
P4
P5
P6
P7
Ql
Q2
Q3
Q4
Q5
Rl
R2
R3 0
-9.470 cf. above R4 1
-26.29 R5 27
1 Result is displayed as an integer with no ad- R6 40
ditional decimal place R7 27
13 unitmg/1 SI 1
200 200 sample volume S2 10
30 lower limit of the assay range S3 00
10000 upper limit of the assay range S4 09
0 lower limit of the reference interval S5 10
100 upper limit of the reference interval S6 01
5 first diluent (= glycine buffer) S7 1
0. normal flush Ml 16
number of flushes M2 00
1750 volume of flush M3 08
4800 diluent applied to analyzer pack M4 05
0 no second diluent M5 13
0000 volume of second diluent M6 00
preheater on
one incubation cycle
breaker/mixer 1 cycle number
delay breaker/mixer 2 (no delay)
breaker/mixer 2 cycle number
end point determination
suppress time of pack
not in use
first filter 577 nm
second filter 600 nm
number of measurement counts
linear calculation
method name
method name
method name
method name
method name
method name
a
 available on request
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